Sequences and methods for delivery of DNA and RNA

The use of expression vectors with DTS and TFBS sequences, combined with lipid nanoparticle formulations, addresses the challenge of nuclear delivery for synthetic vectors, achieving effective gene expression in liver cells and offering new avenues for liver-directed gene therapies.

WO2024236504A1PCT designated stage expired Publication Date: 2024-11-21TAKEDA PHARMA CO LTD
View PDF 20 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/054730
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-15
Filing Date
2024-05-15
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current synthetic vectors face challenges in efficiently delivering DNA and RNA into the cell nucleus for genetic therapies, particularly for liver-directed gene therapies, due to limitations in nuclear targeting and large-scale production and safety issues associated with viral vectors.

Method used

The development of expression vectors incorporating DNA nuclear targeting sequences (DTS) and transcription factor binding sites (TFBS) consensus sequences, along with lipid nanoparticle formulations, to enhance the delivery of genes such as ATP7B and alpha-galactosidase into liver cells, facilitating nuclear targeting and gene expression.

Benefits of technology

The proposed method significantly improves the expression of target genes in liver cells, demonstrated by increased ATP7B and luciferase activity, indicating enhanced nuclear delivery and therapeutic potential for liver-directed gene therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000035_0001
    Figure IMGF000035_0001
  • Figure IMGF000035_0002
    Figure IMGF000035_0002
  • Figure IMGF000035_0003
    Figure IMGF000035_0003
Patent Text Reader

Abstract

The present disclosure relates to sequences and methods for delivery of DNA and RNA using, for example, DNA nuclear targeting sequences (DTSs). These sequences provide more efficient delivery of target DNA and RNA into cells. These sequences are also particularly effective for targeting liver cells, for example, for treatment of inherited liver and systemic disorders, as well as acquired genetic disorders, and also serve as a treatment method for numerous diseases and disorders.
Need to check novelty before this filing date? Find Prior Art

Description

SEQUENCES AND METHODS FOR DELIVERY OF DNA AND RNACROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to and benefit of U.S. Provisional Application No. 63 / 502,389, filed May 15, 2023, which is hereby incorporated by reference in its entirety.REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

[0002] The content of the electronically submitted sequence listing (Name:3817_202PC01_SequenceListing_ST26.xml, Size: 66,621 bytes, and Date of Creation: April 29, 2024) is incorporated by reference in its entirety.FIELD

[0003] The present disclosure relates to sequences and methods for delivery of DNA and RNA.BACKGROUND

[0004] Viral vectors have three major qualities that make them preferred for nuclear DNA delivery including protected / encapsulated genetic material, incorporated delivery machinery, and targeted nuclear delivery. Use of synthetic and non-viral vectors for delivery of DNA to the nucleus of cells, however, is considered essential for future gene therapies, given the fundamental problems associated with viral vectors with regard to large-scale production and safety issues.

[0005] Recent advances in synthetic vectors have made some improvements in delivery, but efficient delivery of DNA and RNA into the nucleus still remains a significant hurdle for synthetic vectors. As such, there remains a need for improvement of delivery methods to the cell nucleus for genetic therapies. Because the liver plays a major role in many inherited liver and systemic disorders, as well as acquired genetic disorders, it can serve as a treatment site for numerous diseases and disorders. Efficient delivery of DNA and RNA to the nucleus of liver cells may lead to new therapeutic avenues for liver-directed gene therapy and gene repair.BRIEF SUMMARY

[0006] In some aspects, the present disclosure relates to an expression vector comprising a DNA nuclear targeting sequence (DTS) region or transcription factor binding site (TFBS). In some aspects, the expression vector comprises a DTS region that comprises a TFBS consensus sequence of any one of SEQ ID NOs: 1-9. In some aspects, the DTS region comprises one TFBS consensus sequence, two TFBS consensus sequences, three TFBS consensus sequences, four TFBS consensus sequences, five TFBS consensus sequences, six TFBS consensus sequences, seven TFBS consensus sequences, eight TFBS consensus sequences, nine TFBS consensus sequences, 10 TFBS consensus sequences, 11 TFBS consensus sequences, 12 TFBS consensus sequences, 13 TFBS consensus sequences, 14 TFBS consensus sequences, or 15 TFBS consensus sequences. In some aspects, the DTS region comprises eight TFBS consensus sequences of SEQ ID NO: 1; seven TFBS consensus sequences of SEQ ID NO: 2; eight TFBS consensus sequences of SEQ ID NO: 3; seven TFBS consensus sequences of SEQ ID NO: 4; seven TFBS consensus sequences of SEQ ID NO: 5; eight TFBS consensus sequences of SEQ ID NO: 6; four TFBS consensus sequences of SEQ ID NO: 7 and four TFBS consensus sequences of SEQ ID NO: 8; or eight TFBS consensus sequences of SEQ ID NO: 9.

[0007] In some aspects, one or more of the TFBS consensus sequences are separated from each other by a spacer having a sequence of one nucleotide, two nucleotides, three nucleotides, four nucleotides, five nucleotides, six nucleotides, seven nucleotides, eight nucleotides, nine nucleotides, or 10 nucleotides. In some aspects, the spacer has a nucleotide sequence of AGA, TCG, GAC, CTA, ACT, TGC or GTA.

[0008] In some aspects, the present disclosure relates to an expression vector comprising a DTS region, wherein the DTS region comprises a sequence of any one of SEQ ID NOs: 10-17.

[0009] In some aspects, the expression vector further comprises a promoter. In some aspects, the promoter is suitable for gene expression in mammalian cells, tissues or organs. In some aspects, the promoter is suitable for gene expression in the liver.

[0010] In some aspects, the expression vector further comprises a gene of interest. In some aspects, the gene of interest is expressed in mammalian cells, tissues or organs. In some aspects, the gene of interest may be expressed in the liver. In some aspects, the gene of interest is ATP7B or a codon optimized version thereof as described herein. In someaspects, the gene of interest is alpha-galactosidase (GLA). In some aspects, the gene of interest is a reporter gene. In some aspects the reporter gene is luciferase.

[0011] In some aspects, the expression vector further comprises a post-transcriptional regulatory element. In some aspects, the post-transcriptional regulatory element is derived from WPRE.

[0012] In some aspects, the expression vector further comprises a termination signal. In some aspects, the termination signal is derived from bGH pA.

[0013] In some aspects, the expression vector is a plasmid, nanoplasmid, other closed-end double strand DNA (minicircle, etc.), or viral vector.

[0014] In some aspects, the present disclosure relates to a lipid nanoparticle formulation comprising an expression vector provided herein.

[0015] In some aspects, the present disclosure relates to a cell comprising an expression vector provided herein.

[0016] In some aspects, the present disclosure relates to a liver cell comprising an expression vector provided herein.

[0017] In some aspects, the present disclosure relates to a nucleic acid molecule comprising the sequence of any one of SEQ ID NOs: 1-9.

[0018] In some aspects, the present disclosure relates to a nucleic acid molecule comprising the sequence of any one of SEQ ID NOs: 10-17, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 10-17.

[0019] In some aspects, the present disclosure relates to a nucleic acid molecule comprising the sequence of any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28.

[0020] In some aspects, the present disclosure relates to a method for expression of a gene of interest in a cell, comprising introducing an expression vector comprising a promoter, a gene of interest, and a DTS region to the cell, wherein the DTS region comprises a TFBS consensus sequence of any one of SEQ ID NOs: 1-9.

[0021] In some aspects, the present disclosure relates to a method for expression of a gene of interest in a cell, comprising introducing an expression vector comprising a promoter, a gene of interest, and a DTS region to the cell, wherein the DTS region comprises a sequence of any one of SEQ ID NOs: 10-17, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 10-17.

[0022] In some aspects, the present disclosure relates to a method for introducing a gene of interest into the nucleus of a cell, comprising introducing an expression vector comprising a promoter, a gene of interest, and a DTS region to the cell, wherein the DTS region comprises a TFBS consensus sequence of any one of SEQ ID NOs: 1-9.

[0023] In some aspects, the present disclosure relates to a method for introducing a gene of interest into the nucleus of a cell, comprising introducing an expression vector comprising a promoter, a gene of interest, and a DTS region to the cell, wherein the DTS region comprises a sequence of any one of SEQ ID NOs: 10-17, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 10-17.

[0024] In some aspects, the cell is a liver cell. In some aspects, the gene of interest is ATP7B or a codon optimized version thereof as described herein.BRIEF DESCRIPTION OF THE DRAWINGS / FIGURES

[0025] FIG. l is a pictorial representation of plasmid constructs comprising, in some examples, a DTS region of the present disclosure and ATP7B as the gene of interest.

[0026] FIG. 2 is a graphical representation of expression of ATP7B in pg / pg of cell protein in human primary hepatocytes.

[0027] FIG. 3 is a pictorial representation of plasmid and Nanoplasmid™ constructs comprising, in some examples, a TFBS consensus sequence of the present disclosure and luciferase as a reporter gene linked by P2A to human GLA therapeutic transgene.

[0028] FIG. 4 is a graphical representation of luminescence of luciferase in relative light units (RLU) from cytoplasm of hepatocytes following transformation with the indicated plasmids.

[0029] FIGs. 5A-5B are graphical representations of luminescence of luciferase from cytoplasm following transformation of hepatocytes with the indicated Nanoplasmids™. FIG. 5 A represents luciferase luminescence in relative fluorescence units RFU. And FIG. 5B represents RFU per pg protein per mL.

[0030] FIG. 6 is a graphical representation of luciferase luminescence in RLU and ATP7B concentration in pg / pg of cell protein.DETAILED DESCRIPTION

[0031] Some aspects of the present disclosure are directed to a method of targeting DNA or RNA to the cell nucleus. Some aspects of the present disclosure are also directed to a method of targeting DNA or RNA to the cell nucleus of mammalian cells. Some aspects of the disclosure are related to expression of DNA or RNA in liver cells. Some aspects of the disclosure are directed to vectors for nuclear targeting. Some aspects of the disclosure are directed to sequences for nuclear DNA or RNA delivery.

[0032] Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to the particular compositions or process steps described, as such can, of course, vary. As will be apparent to those of skill in the art upon reading this disclosure, each of the individual aspects described and illustrated herein has discrete components and features which can be readily separated from or combined with the features of any of the other several aspects without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.

[0033] The headings provided herein are not limitations of the various aspects of the disclosure, which can be defined by reference to the specification as a whole. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only, and is not intended to be limiting.I. Terms

[0034] In order that the present disclosure can be more readily understood, certain terms are first defined. As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout the application.

[0035] As described herein, any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated.

[0036] Throughout this disclosure, the term "a" or "an" entity refers to one or more of that entity; for example, "a TFBS consensus sequence," is understood to represent one or more TFBS consensus sequences. As such, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein.

[0037] Furthermore, "and / or" where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term "and / or" as used in a phrase such as "A and / or B" herein is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Likewise, the term "and / or" as used in a phrase such as "A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone). In addition, "or" is used mean an open list of the components in the list. For example, "wherein X comprises A or B" means X comprises A, X comprises B, X comprises A and B, or X comprises A or B and any other components.

[0038] The term "about" refers to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, / .< ., the limitations of the measurement system. For example, "about" can mean within 1 or more than 1 standard deviation per the practice in the art. Alternatively, "about" or "comprising essentially of' can mean a range of up to 10%. Furthermore, particularly with respect to biological systems or processes, the terms can mean up to an order of magnitude or up to 5-fold of a value. When particular values or compositions are provided in the application and claims, unless otherwise stated, the meaning of "about" should be assumed to be within an acceptable error range for that particular value or composition.

[0039] As used herein, the term "approximately," as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain aspects, the term "approximately" refers to a range of values that fall within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the statedreference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

[0040] The term "heterologous" refers to any material, e.g., an immune cell, nucleic acid sequence, gene, polypeptide, or other biological matter, derived from another individual or species, i.e., is non-native to the gene sequence, cell, system, or subject to which it is introduced.

[0041] An "acquired disorder" refers to a disorder or disease that is acquired by means other than genetic inheritance. Examples of an acquired disorder that can be treated by the methods of the present disclosure include various infectious diseases, e.g., Hepatitis B and C, Malignant neoplasms including hepatomas, cholangiocarcinomas, metastatic tumors, extrahepatic tumors (inhibition of neovascularization), a cancer, Cirrhosis of the liver, and allograft or xenograft rejection.

[0042] An "inherited liver disorder" refers to a group of disorders affecting the liver that are inherited or conferred genetically. Examples of inherited liver disorders that can be treated by the methods of the present disclosure include Crigler-Najjar syndrome type 1, Familial hypercholesterolemia and other lipid metabolic disorders, Maple syrup urine disease, Progressive familial intrahepatic cholestasis, Phenylketonuria, Tyrosinemia, Mucopolysaccharidosis VII, al -antitrypsin (AAT) deficiency, Ornithine transcarbamylase deficiency, Wilson's disease, Glycogen storage diseases, e.g., von Gierke's disease and Pompe's disease, Hyperbilirubinema, Acute intermittent porphyria, and Citrullinemia type 1.

[0043] An "inherited systemic disorder" refers to a group of disorders affecting the whole system or body and are inherited or conferred genetically. Examples of an inherited systemic disorder that can be treated by the methods of the present disclosure include Hemophilia A and B, Fabry disease, and Oxalosis.

[0044] A "cancer" refers to a broad group of various diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division and growth results in the formation of malignant tumors that invade neighboring tissues and may also metastasize to distant parts of the body through the lymphatic system or bloodstream. A "cancer" or "cancer tissue" can include a tumor. Examples of cancers that can be treated by the methods of the present disclosure include, but are not limited to, cancers of the immune system including lymphoma, leukemia, and other leukocyte malignancies. In some aspects, the methods of the present invention can be used to reduce the tumor sizeof a tumor derived from, for example, the cancer comprises bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, breast cancer, prostate cancer, lung cancer (e.g. , non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), Hodgkin's Disease, nonHodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, or any combination thereof. The particular cancer can be responsive to chemo- or radiation therapy or the cancer can be refractory. A refractory cancer refers to a cancer that is not amendable to surgical intervention, and the cancer is either initially unresponsive to chemo- or radiation therapy or the cancer becomes unresponsive over time.

[0045] It is understood that wherever aspects are described herein with the language "comprising," otherwise analogous aspects described in terms of "consisting of and / or "consisting essentially of' are also provided.

[0046] As used herein, the term "introducing" or "introduction" or "transformation" or "transduction" or "transfection" refers to expressing a heterologous polynucleotide and / or polypeptide in a cell. In some aspects, introduction is achieved by transfecting the cell with a polynucleotide of interest. In some aspects, introduction is achieved by genetically modifying the cell to express a heterologous sequence, e.g., using a gene editing tool including, but not limited to, a vector, viral vector, plasmid, Nanoplasmid™, CRISPR / Cas, CRISPR / Cas9, CRISPR / Casl2, CRISPR / Casl2a, CRISPR / Cpfl, zinc finger, TALEN, Closver-Cas, Sleeping Beauty transposon, PiggyBac transposon, or a variant thereof. In some aspects, introduction is achieved by contacting the cell with adouble strand DNA, such as DNA plasmid, DNA Nanoplasmid™, doggybone DNA, ministring DNA, or any dumbbell-shaped DNA encoding a gene sequence of interest, such that the DNA enters into the cell, and / or preferably the nucleus of the cell. In some aspects, introduction comprises transfecting or transducing a cell with a polynucleotide encoding a polypeptide.

[0047] The term "hepatocyte" as used herein refers to a type of liver cell.

[0048] The term "DNA nuclear targeting sequence" or "DTS" or "DTS sequence" or "DTS region" refers to a deoxyribonucleic acid (DNA) sequence that aids in delivery of genetic material to a targeted location of a cell, for instance, the nucleus. More specifically, a DTS region contains one or more sequences to which a transcription factor binds, referred to herein as a "transcription factor binding site" or "TFBS" or "TFBS sequence" or "TFBS consensus sequence." In some aspects, a DTS region can include, for example, one or more TFBS consensus sequences, and optionally, one or more spacers. Examples of a DTS region include, but are not limited to, any one of SEQ ID NOs: 10-17, as presented in Table 1. Examples of a TFBS consensus sequence, include, but are not limited to, any one of SEQ ID NOs: 1-9, as presented in Table 1.Table 1. DNA Nuclear Targeting Sequences

[0049] The term "spacer" refers to one or more nucleotides or nucleosides, for example, a nucleotide represented by adenine (A), guanine (G), thymine (T), and cytosine (C), or variants thereof, that lies between two TFBS consensus sequences. The spacer may comprise a sequence of one nucleotide, two nucleotides, three nucleotides, four nucleotides, five nucleotides, six nucleotides, seven nucleotides, eight nucleotides, nine nucleotides, or 10 nucleotides. Examples of a spacer include, but are not limited to, AGA, TCG, GAC, CTA, ACT, TGC and GTA.

[0050] A "post-transcriptional regulatory element" as used herein refers to a nucleotide sequence or gene that controls gene expression at the RNA level and acts by affecting RNA transcription. The terms "transcriptional regulatory protein," "transcriptional regulatory factor," and "transcription factor" are used interchangeably herein, and refer to a nuclear protein that binds a DNA response element and thereby transcriptionallyregulates the expression of an associated gene or genes. Transcriptional regulatory proteins generally bind directly to a DNA response element, however in some cases binding to DNA can be indirect by way of binding to another protein that in turn binds to, or is bound to a DNA response element. Post-transcriptional regulatory elements (PREs) may include PREs derived from Woodchuck Hepatitis virus (WPRE), or Hepatitis B virus (HPRE).

[0051] A "termination signal" as used herein refers to a nucleotide or DNA sequence that signals end of transcription of translation. A termination signal may include bGH polyA (pA) or a bGH pA-derived sequence. Additional polyA signals include those from SV40, rabbit alpha-globin, rabbit beta-globin, human beta-globin, HIV, human growth hormone (HGH), or synthetically created sequences.

[0052] As used herein, the term "modified" refers to a changed state or structure of a molecule of the disclosure. Molecules can be modified in many ways including chemically, structurally, and functionally.

[0053] As used herein, the term "synthetic" means produced, prepared, and / or manufactured by the hand of man. Synthesis of polynucleotides or polypeptides or other molecules of the present disclosure can be chemical or enzymatic. In some aspects, the synthetic promoter of the disclosure is not naturally occurring.

[0054] As used herein, the term "promoter" refers to a DNA sequence recognized by the machinery of the cell, or introduced synthetic machinery, that can initiate the transcription of a nucleic acid (e.g., a gene of interest). The term "promoter" can also encompass those nucleic acid elements sufficient for promoter-dependent gene expression controllable for cell-type specific, tissue-specific or inducible by external signals or agents; such elements can be located in the 5' or 3' regions of the native gene. In some aspects, the promoter is a constitutive promoter, a cell-type specific promoter, or an inducible promoter. The term promoter may refer to a promoter suitable for gene expression in the liver. Suitable promoters may include but are not limited to CMV promoter, CAG promoter, TTR promoter, HP1, TATA box, Pol-II, LTR, Elongation Factor 1 alpha (EFla), PGK, CMVIE, hSynl, spC5.12 Promoter, hTTR, hAAT, and others known in the art which may be referenced in the publication Analysis of Promoters for Liver-Directed Expression (Tissue Targeted Gene Expression and Imaging, No. 1252 by Yu et al., Molecular Therapy, Vol. 5, No. 5, May 2002, Part 2 of 2, p. S408).

[0055] The term "CAG promoter" refers to a hybrid nucleic acid construct consisting of the cytomegalovirus (CMV) enhancer fused to the chicken P-actin (CAG) promoter, which has been shown to give high levels of transgene expression in several cell lines and allows expression in various mammalian cells, tissues and organs.

[0056] The term "human Transthyretin (TTR) promoter" refers to a hybrid nucleic acid construct consisting of the promoter for the transthyretin (TTR) protein. The TTR promoter controls hepatocyte-specific expression.

[0057] The term "gene of interest" may refer to any gene or nucleotide fragment that is desired to be targeted to a cell, especially a liver cell, or nucleus of a cell, especially a liver cell.

[0058] The term "ATP7B" refers to the ATP7B gene that provides instruction for making a protein known as copper-transporting ATPase 2, and its corresponding protein or polypeptide. The copper-transporting ATPase 2 protein is part of the P-type ATPase family, a group of proteins that transport metals into and out of cells by using energy stored in the molecule adenosine triphosphate (ATP). The ATP7B protein is located in the trans-Golgi network of the liver and brain and balances the copper level in the body by excreting excess copper into bile and plasma. Genetic disorder of the ATP7B gene is thought to cause Wilson's disease wherein copper accumulates in tissues leading to neurological and psychiatric issues as well as liver disease.

[0059] As used herein, the term "ATP7B" includes, but is not limited to, a codon optimized recombinant form of the ATP7B gene, such as a polynucleotide having the sequence of any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28, as presented in Table 2, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28.

[0060] As used herein, the term "ATP7B" also includes, but is not limited to, a polypeptide having the sequence of any one of SEQ ID NOs: 19, 21, 23, 25, 27 and 29, as presented in Table 2, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 19, 21, 23, 25, 27 and 29.

[0061] As used herein, the term "ATP7B" also includes, but is not limited to, a polypeptide encoded by a polynucleotide having the sequence of any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28, as presented in Table 2, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28.

[0062] As used herein, the term "ATP7B" also includes, but is not limited to, a polynucleotide encoding a polypeptide having the sequence of any one of SEQ ID NOs: 19, 21, 23, 25, 27 and 29, as presented in Table 2, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 19, 21, 23, 25, 27 and 29. These example gene and protein sequences target proteins to specific organs or tissues, for example, human liver tissue. They were further designed via CAI or CC design methods with or without CpG regions, as indicated in Table 2.Table 2. Codon Optimized ATP7B Sequences

[0063] As used herein, the term "CpG" or "CpG region" or "CpG island" refers to a linear DNA sequence in which cytosine (C) and guanine (G) bases are connected by a phosphate group from base pairing of C to G. Mammalian DNA methylation occurs at CpG sites within the DNA. In humans, about 70% of annotated gene promoters are associated with CpG islands, including almost all housekeeping genes. CpG islands in these promoters are usually unmethylated, which means that these genes can be transcribed by transcription factors (Personalized Epigenetics, M. Bitzer, N.P. Malek, in Medical Epigenetics, 2016).

[0064] The term "CAI" refers to codon adaptation index. A codon refers to three DNA nucleotides that encode or code for an amino acid. There are a number of codons, or synonymous codons, that may encode for the same amino acid and different organisms rely on different codon usage. To optimize DNA sequences for different organisms it can be important to select codons appropriate to that organism. To take the different numberof synonymous codons into account, one can define the "relative synonymous codon usage" (RSCU / ), which describes the relation between the observed codon usage and the statistically expected fraction for equally frequently used codons (Sharp and Li, The codon adaption index-a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res. 1987; 15(3): 1281 -1295).

[0065] Alternatively, the "relative adaptiveness" w tj may be used, which is defined as:

[0066] where c y max denotes the codon usage of the most frequently used codon j for a certain amino acid i.

[0067] The geometric mean of the w values for L codons is known as the codon adaption index, or CAI, defined by the formula below, which indicates how well a coding sequence represents the codon usage of a given organism. For example, a sequence where only the most frequently used codon for each amino acid is used, would have a CAI value of 1 (Raab, D, et al., The Gene Optimizer Algorithm: using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization, Syst Synth Biol., Vol. 4(3), Sep. 2010). CAI may be calculated using the following formula.

[0068] As used herein, the term "CC" refers to codon context, and the term "CCO" refers to codon context optimization, a codon optimization method which optimizes sequences based on codon context only (Chung and Lee, Computational codon optimization of synthetic gene for protein expression, BMC Systems Biology, Vol. 6, Article no. 134, 2012). Programs for CCO may be accessed through bioinfo. bti.a- star.edu. sg / tool / CodonOptimization / (Chung and Lee, 2012).

[0069] Codon optimization of the sequences described herein was done using the COOL algorithm. "COOL" or "Codon Optimization Online" refers to a web-based codon optimization tool supported by the National Library of Medicine, National Center forBiotechnology Information. COOL provides the multi-objective codon optimization functionality to aid systematic synthetic gene design (Chin, J. X. et al., Codon Optimization OnLine (COOL): a web-based multi-objective optimization platform for synthetic gene design, Bioinformatics, 2014 Aug 1 ;30(l 5):2210-2, electronically published 2014 Apr 10) and can be accessed at bioinfo. bti.a-star.edu.sg / COOL / .

[0070] As used herein, the term "GLA" refers to the GLA gene and enzyme alphagalactosidase that catalyzes break down of fatty acids or lipids into smaller components.

[0071] As used herein, the term "MVM intron" refers to a small-intron region of minute virus of mice (MVM) pre-mRNAs that undergo a pattern of overlapping alternative splicing using, for example, two donors (DI and D2) and two acceptors (Al and A2) within a region of 120 nucleotides, that determines the steady-state ratios of the various viral mRNAs.

[0072] As used herein, the term "enhancer" is a cis-acting element that stimulates or inhibits transcription of adjacent genes. An enhancer that inhibits transcription is also referred to as a "silencer." Enhancers can function (e.g., can be associated with a coding sequence) in either orientation, over distances of up to several kilobase pairs (kb) from the coding sequence and from a position downstream of a transcribed region. Examples of an enhancer include, but are not limited to, a CRM8 enhancer, ApoE, CMV, MCK, CRM1 and CRM14.

[0073] The term "expression vector" or "expression construct" means any type of genetic construct containing a nucleic acid in which part or all of the nucleic acid encoding sequence is capable of being transcribed.

[0074] As used herein, the term "delivery vector" or "vector" refers to any vehicle for the cloning of and / or transfer of a nucleic acid into a host cell, such as a plasmid, Nanoplasmid, phage, transposon, cosmid, chromosome, artificial chromosome, virus, virion, etc. A vector can be a replicon to which another nucleic acid segment can be attached so as to bring about the replication of the attached segment. A "replicon" refers to any genetic element (e.g., plasmid, phage, cosmid, chromosome, virus) that functions as an autonomous unit of replication in vivo, i.e., capable of replication under its own control. The term "delivery vector" or "vector" includes both viral and nonviral vehicles for introducing the nucleic acid into a cell in vitro, ex vivo or in vivo. A large number of vectors, synthetic, non- synthetic, or partially synthetic are known and used in the art including, for example, plasmids, Nanoplasmids, modified eukaryotic viruses, ormodified bacterial viruses, minicircles, GenCircle, and closed-end linear double strand DNA (Touchlight, Mediphage). DNA vectors may include, for example, circular double stranded DNA vectors such as plasmids, nanoplasmids, minicircles, and GenCircles, circular single strand DNA, linear double strand DNA, such as a PCR product, linear single strand DNA, and closed-end double stand DNA, such as doggybone, ministring, or dumbbell DNA. In some aspects, insertion of a polynucleotide into a suitable vector can be accomplished by ligating the appropriate polynucleotide fragments into a chosen vector that has complementary cohesive termini. Vectors can be engineered to encode selectable markers or reporters that provide for the selection or identification of cells that have incorporated the vector. Expression of selectable markers or reporters allows identification and / or selection of host cells that incorporate and express other coding regions contained on the vector. Examples of selectable marker genes known and used in the art include: genes providing resistance to ampicillin, streptomycin, gentamycin, kanamycin, hygromycin, bialaphos herbicide, sulfonamide, and the like; and genes that are used as phenotypic markers, / .< ., anthocyanin regulatory genes, isopentanyl transferase gene, and the like. Selectable markers can also be considered to be reporter genes. In some aspects, the delivery vector is selected from the group consisting of a viral vector (e.g., an AAV vector), a plasmid, Nanoplasmid, bacterial artificial chromosome (BAC), yeast artificial chromosome, a bacteriophage, a cosmid, a human artificial chromosome, a lipid, a protein particle, a bacterial vector, and a lysosome. Vectors vary in size and amount of DNA that can be cloned into them. The plasmid, for example, may be an SV40 plasmid.

[0075] As used herein the term "reporter gene" refers to a gene is a gene whose product can be used as a reporter or marker for screening successful transfection, gene expression, regulation of gene expression, or a control reporter for measuring effectiveness of transfection or gene expression. Examples of reporter genes may include, but are not limited to luciferase, green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), enhanced yellow fluorescent protein (EYFP / YFP), enhanced cyan fluorescent protein (ECFP / CFP), P-glucuronidase (GUS), chloramphenicol acetyltransferase (CAT), and P-galactosidase (lacZ). Luciferases may include beetle luciferases, including firefly luciferase, Renilla luciferase and a modified deep sea shrimp luciferase (NanoLuc® luciferase). Luciferase genes have been cloned from bacteria, beetles (e.g., firefly),Renilla, deep sea shrimp (Oplophorus), Aequorea, Vargula and Gonyaulax (a dinoflagellate).

[0076] As such used herein, a "plasmid" or "Nanoplasmid" or "plasmid backbone" are sequences that originate with the plasmid which may include cloning sites, promoters, and / or regulatory or selection sequences prior to cloning gene of interest. A plasmid generally is approximately 3000-4500 base pair, or larger. A Nanoplasmid™ (Aldevron) is a small plasmid with less than 500 bp backbone. Plasmids carrying genes of interest presented herein may be as large as 7000 bp, or as large as 8000 bp, or larger. Nanoplasmids presented herein carrying genes of interest may be as large as 500 bp or larger, or as large as 1000 bp or larger, or as large as 2000 bp or larger, or as large as 3000 bp, or as large as 4000 bp, or 5000 bp, or 6000 bp or larger, or less than 7000 bp.

[0077] The term "base pair" or "bp" as used herein refers to a single nucleoside or nucleotide base that makes up a nucleic acid molecule. A "kilobase" or "kb" is one- thousand bp, i.e., 1000 bp. Nucleoside / nucleotide bases are generally pyrimidine or purine bases and in the case of deoxyribonucleic acid (DNA), or deoxynucleotide, bases include cytosine and thiamine purine bases, and adenosine and guanine pyrimidine bases.

[0078] "Nucleic acid," "nucleic acid molecule," "nucleotide sequence," "polynucleotide," "oligonucleotide," and grammatical variants thereof are used interchangeably and refer to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules"), or any phosphoester analogs thereof, such as phosphorothioates and thioesters, in either single stranded form, or a double-stranded helix. Single stranded nucleic acid sequences refer to single-stranded DNA (ssDNA) or single-stranded RNA (ssRNA). Double stranded DNA-DNA, DNA- RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear or circular DNA molecules e.g., restriction fragments), plasmids, supercoiled DNA and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences can be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the non-transcribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that hasundergone a molecular biological manipulation. DNA includes, but is not limited to, cDNA, genomic DNA, plasmid DNA, synthetic DNA, and semi-synthetic DNA. A "nucleic acid composition" of the disclosure comprises one or more nucleic acids as described herein.

[0079] As used herein "lipid nanoparticle" or "LNP" refers to a class of nanoparticles or nano-sized particles composed of lipids. The lipids form porous spheres and can encapsulate or surround drugs, therapeutics, vaccines, and nucleotides like DNA and RNA oligonucleotides or vectors. Various lipids can be utilized to create LNPs including ionizable-lipids, which may be cationic or anionic lipids, helper lipids, cholesterol, PEG- DMG, or other lipids, as described further herein. These can be mixed in various formulations and molar ratios to achieve desired size and qualities.

[0080] As used herein, the term "polypeptide" is intended to encompass a singular "polypeptide" as well as plural "polypeptides," and comprises any chain or chains of two or more amino acids. Thus, as used herein, a "peptide," a "peptide subunit," a "protein," an "amino acid chain," an "amino acid sequence," or any other term used to refer to a chain or chains of two or more amino acids, are included in the definition of a "polypeptide," even though each of these terms can have a more specific meaning. The term "polypeptide" can be used instead of, or interchangeably with any of these terms. The term further includes polypeptides which have undergone post-translational or postsynthesis modifications, for example, conjugation of a palmitoyl group, glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, or modification by non-naturally occurring amino acids. The term "peptide," as used herein encompasses full length peptides and fragments, variants or derivatives thereof. A "peptide" as disclosed herein, can be part of a fusion polypeptide comprising additional components such as, e.g., an Fc domain or an albumin domain, to increase half-life. A peptide as described herein can also be derivatized in a number of different ways. A peptide described herein can comprise modifications including e.g., conjugation of a palmitoyl group.

[0081] As used herein, the term "in vitro" refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, in a Petri dish, etc., rather than within an organism (e.g., animal, plant, or microbe).

[0082] As used herein, the term "in vivo" refers to events that occur within an organism (e.g., animal, plant, or microbe or cell or tissue thereof).

[0083] As used herein, "pharmaceutically acceptable carrier" includes any and all aqueous solvents (e.g., water, alcoholic / aqueous solutions, saline solutions, parenteral vehicles, such as sodium chloride, Ringer's dextrose, etc.), non-aqueous solvents (e.g., propylene glycol, polyethylene glycol, vegetable oil, and injectable organic esters, such as ethyloleate), dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial or antifungal agents, anti-oxidants, chelating agents, and inert gases), isotonic agents, absorption delaying agents, salts, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, fluid and nutrient replenishers, such like materials and combinations thereof, as would be known to one of ordinary skill in the art. The pH and exact concentration of the various components in a pharmaceutical composition are adjusted according to well-known parameters.

[0084] The term "recombinant" or "modified" cell, as used herein, is intended to refer to a cell, e.g., an immune cell, that comprises a nucleic acid that is not naturally present in the cell, and can be a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but also to the progeny of such a cell. Though certain modifications can occur in succeeding generations due to either mutation or environmental influences, such progeny are still included within the scope of the term "recombinant" or "modified" as used herein.

[0085] As used herein, the terms "subject" and "patient" are used interchangeably and refer to either a human or a non-human, such as primates, mammals, and vertebrates. In particular aspects, the subject is a human.

[0086] The term "therapeutic benefit" or "therapeutically effective," as used herein, refers to anything that promotes or enhances the well-being of the subject with respect to the medical treatment of this condition. This includes, but is not limited to, a reduction in the frequency or severity of the signs or symptoms of a disease.

[0087] As used herein, the term "treating" or "treatment" of a disease or condition refers to executing a protocol, which may include administering one or more therapies to a patient, in an effort to alleviate signs or symptoms of the disease. In some aspects, a treatment decreases the rate of disease progression, ameliorates or palliates the disease state, and / or facilitates remission or improved prognosis. Alleviation can occur prior to signs or symptoms of the disease or condition appearing, as well as after their appearance.Thus, in some aspects, "treating" or "treatment" includes "preventing" or "prevention" of a disease or an undesirable condition. However, "treating" or "treatment" does not require complete alleviation of all signs and / or symptoms, does not require a cure, and specifically includes protocols that have only a marginal effect on the patient.

[0088] In various aspects, a subject in need thereof may be treated for a disease or for alleviating symptoms associated with a disease (e.g., an inherited liver or system disorder, acquired disorder, or cancer) using a vector described herein. In some aspects, the vector(s) are transduced to other cells to produce modified cells, such that the modified cells are less susceptible to killing by the subject's immune system when such cells are administered to the subject.

[0089] As used herein, the terms "ug", "uL" and "uM" are used interchangeably with "pg", "pL", and "pM," respectively.

[0090] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary of Biochemistry and Molecular Biology, Revised, 2000, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure.

[0091] Units, prefixes, and symbols are denoted in their Systeme International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. As described herein, any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one-tenth and one-hundredth of an integer), unless otherwise indicated.

[0092] Abbreviations used herein are defined throughout the present disclosure. Various aspects of the disclosure are described in further detail in the following subsections.

[0093] Various aspects described herein are described in further detail in the following subsections.II. Compositions of the Disclosure

[0094] Some aspects of the present disclosure are directed to a DTS region that contains one or more TFBS consensus sequences. In some aspects, the TFBS consensus sequencemay be represented by any one of SEQ ID NOs: 1-9. In some aspects, the DTS region may comprise a DNA oligonucleotide having the formula (TFBSxm)n, wherein TFBS represents a TFBS consensus sequence, such as any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8 and 9; x represents any deoxyribonucleotide base; m represents any integer 0 to 9; and n represents any integer 1 to 20. Further, the DTS region may be represented by the following formula (TFBSlxmTFBS2xm)n, wherein TFBS1 represents any TFBS consensus sequence, such as any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8 and 9; and TFBS2 represents any TFBS consensus sequence, such as any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8 and 9; x represents any deoxyribonucleotide base; m represents any integer 0 to 9; and n represents any integer 1 to 20.

[0095] In some aspects, a DTS region may comprise at least one TFBS consensus region. For example, the DTS region may comprise at least two TFBS consensus sequences. The DTS region may comprise at least three TFBS consensus sequences. The DTS region may comprise at least four TFBS consensus sequences. The DTS region may comprise at least five TFBS consensus sequences. The DTS region may comprise at least six TFBS consensus sequences. The DTS region may comprise at least seven TFBS consensus sequences. The DTS region may comprise at least eight TFBS consensus sequences. The DTS region may comprise at least nine TFBS consensus sequences. The DTS region may comprise at least 10 TFBS consensus sequences. The DTS region may comprise at least 11 TFBS consensus sequences. The DTS region may comprise at least 12 TFBS consensus sequences. The DTS region may comprise at least 13 TFBS consensus sequences. The DTS region may comprise at least 14 TFBS consensus sequences. The DTS region may comprise at least 15 TFBS consensus sequences.

[0096] In some aspects, the DTS region may comprise eight TFBS consensus sequences of SEQ ID NO: 1. The DTS region may comprise seven TFBS consensus sequences of SEQ ID NO: 2. The DTS region may comprise eight TFBS consensus sequences of SEQ ID NO: 3. The DTS region may comprise seven TFBS consensus sequences of SEQ ID NO: 4. The DTS region may comprise seven TFBS consensus sequences of SEQ ID NO: 5. The DTS region may comprise eight TFBS consensus sequences of SEQ ID NO: 6. The DTS region may comprise four TFBS consensus sequences of SEQ ID NO: 7, and four TFBS consensus sequences of SEQ ID NO: 8. The DTS region may comprise eight TFBS consensus sequences of SEQ ID NO: 9.

[0097] In some aspects, the TFBS consensus sequences of a DTS region may be separated from each other by a spacer having a sequence of at least one nucleotide. For example, the TFBS consensus sequences of a DTS region may be separated from each other by a spacer having a sequence of at least two nucleotides. The TFBS consensus sequences of a DTS region may be separated from each other by a spacer having a sequence of at least three nucleotides. The TFBS consensus sequences of a DTS region may be separated from each other by a spacer having a sequence of at least four nucleotides. The TFBS consensus sequences of a DTS region may be separated from each other by a spacer having a sequence of at least five nucleotides. The TFBS consensus sequences comprising a DTS region may be separated from each other by a spacer having a sequence of at least six nucleotides. The TFBS consensus sequences comprising a DTS region may be separated from each other by a spacer having a sequence of at least seven nucleotides. The TFBS consensus sequences of a DTS region may be separated from each other by a spacer having a sequence of at least eight nucleotides. The TFBS consensus sequences of a DTS region may be separated from each other by a spacer having a sequence of at least nine nucleotides. The TFBS consensus sequences of a DTS region may be separated from each other by a spacer having a sequence of at least 10 nucleotides.

[0098] In some aspects, the TFBS consensus sequences may be separated by a spacer, wherein the spacer has a nucleotide sequence of AGA. The TFBS consensus sequences may be separated by a spacer, wherein the spacer has a nucleotide sequence of TCG. The TFBS consensus sequences may be separated by a spacer, wherein the spacer has a nucleotide sequence of GAC. The TFBS consensus sequences may be separated by a spacer, wherein the spacer has a nucleotide sequence of CTA. The TFBS consensus sequences may be separated by a spacer, wherein the spacer has a nucleotide sequence of ACT. The TFBS consensus sequences may be separated by a spacer, wherein the spacer has a nucleotide sequence of TGC. The TFBS consensus sequences may be separated by a spacer, wherein the spacer has a nucleotide sequence of GTA.

[0099] In some aspects, the DTS region of the present disclosure may be represented by any one of SEQ ID NOs: 10-17. In some aspects, the DTS region of the present disclosure may be represented by a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity toany one of SEQ ID NOs: 10-17. In some aspects, the DTS region may be represented by a sequence having about 90% identity, about 91% identity, about 92% identity, about 93% identity, about 94% identity, about 95% identity, about 96% identity, about 97% identity, about 98% identity, or about 99% identity to any one of SEQ ID NOs: 10-17.

[0100] Some aspects of the present disclosure are directed to vectors comprising one or more TFBS consensus sequences or DTS regions. In some aspects, the vector may be a plasmid. In some aspects, the vector may be a Nanoplasmid™ In some aspects, the vector may be a viral vector. In some aspects, the vector comprises less than 9000 bp. In some aspects, the vector comprises less than 7000 bp.

[0101] In some aspects, the vector further comprises a promoter. In some aspects, the promoter is a promoter suitable for gene expression in various cells, tissues and organs, such as the CAG promoter, or in the liver, such as the TTR promoter. In some aspects, the vector further comprises a gene of interest, such as a gene for targeted therapy of disorders and diseases described herein. In some aspects, the gene of interest is ATP7B, such as a wild-type ATP7B gene sequence or a codon optimized version of ATP7B described herein. In some aspects, the gene of interest is alpha-galactosidase (GLA). In some aspects, the vector further comprises a post-transcriptional regulatory element. In some aspects, the post-transcriptional regulatory element is derived from WPRE. In some aspects, the vector further comprises a termination signal. In some aspects, the termination signal is derived from pGH pA.

[0102] Some aspects of the present disclosure are directed to a “wild-type ATP7B” sequence or “ATP7B” or the ATP7B polypeptide translated therefrom. The wild-type ATP7B or ATP7B is a gene sequence derived from an organism with no engineered or deliberate sequence alterations or mutations.

[0103] Some aspects of the present disclosure are directed to a codon optimized ATP7B sequence. In some aspects, the present disclosure is directed to a polynucleotide comprising the sequence of any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28, as presented in Table 2, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28.

[0104] In some aspects, the present disclosure is directed to a polypeptide comprising the sequence of any one of SEQ ID NOs: 19, 21, 23, 25, 27 and 29, as presented in Table 2,or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 19, 21, 23, 25, 27 and 29.

[0105] In some aspects, the present disclosure is directed to a polypeptide encoded by a polynucleotide having the sequence of any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28, as presented in Table 2, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28.

[0106] In some aspects, the present disclosure is directed to a polynucleotide encoding a polypeptide having the sequence of any one of SEQ ID NOs: 19, 21, 23, 25, 27 and 29, as presented in Table 2, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 19, 21, 23, 25, 27 and 29.

[0107] Some aspects of the present disclosure are directed to a lipid nanoparticle (LNP) formulation comprising an LNP and a nucleotide sequence, vector or expression vector provided herein.

[0108] In some aspects, the LNP comprises an ionizable lipid which may for example comprise a cationic lipid, a non-cationic lipid, or a combination thereof.

[0109] As used herein, a "cationic lipid" means a lipid that has a net positive charge at a selected pH. A cationic lipid used in the lipid nanoparticle of the present disclosure is not particularly limited. For example, cationic lipids described in WO 2015 / 011633, WO 2016 / 021683, WO 2011 / 153493, WO 2013 / 126803, WO 2010 / 054401, WO 2010 / 042877, WO 2016 / 104580, WO 2015 / 005253, WO 2014 / 007398, WO 2017 / 117528, WO 2017 / 075531, WO 2017 / 00414, WO 2015 / 199952, US 2015 / 0239834, WO 2019 / 131839, or WO 2020 / 032184 can be in the lipid nanoparticles of the present disclosure.

[0110] In one aspect, cationic lipids for use in the LNPs of the present disclosure are described in WO 2015 / 011633.[OHl] In another aspect, cationic lipids for use in the LNPs of the present disclosure include:

[0112] and salts thereof.

[0113] In another aspect, cationic lipids for use in the LNPs of the present disclosure are described in WO 2016 / 021683.

[0114] In another aspect, cationic lipids for use in the LNPs of the present disclosure are compounds of the formula:

[0115] wherein:

[0116] W is the formula —NR1R2or the formula —N+R3R4R5(Z−),

[0117] R1and R2are each independently a C1-4 alkyl group or a hydrogen atom,

[0118] R3, R4and R5are each independently a C1-4 alkyl group,

[0119] Z−is an anion,

[0120] X is an optionally substituted C1-6alkylene group,

[0121] YA, YBand YCare each independently an optionally substituted methine group,

[0122] LA, LBand LCare each independently an optionally substituted methylene group or a bond, and

[0123] RA1, RA2, RB1, RB2, RC1and RC2are each independently an optionally substituted C4-10 alkyl group, or a salt thereof.

[0124] In another aspect, cationic lipids for use in the LNPs of the present disclosure include:

[0125] and salts thereof.

[0126] In another aspect, cationic lipids for use in the LNPs of the present disclosure include:

[0127] and salts thereof.

[0128] In another aspect, cationic lipids for use in the LNPs of the present disclosure are compounds of Formula (II):

[0129] wherein

[0130] n is an integer of 2 to 5,

[0131] R is a linear C1-5 alkyl group, a linear C7-11 alkenyl group or a linear C11 alkadienyl group, and

[0132] wavy lines are each independently shows a cis-type or trans-type bond, or a salt thereof.

[0133] In another aspect, cationic lipids for use in the LNPs of the present disclosure include:- LS -

[0134] and salts thereof.

[0135] In another aspect, cationic lipids for use in the LNPs of the present disclosure include:

[0136] and salts thereof.

[0137] In another aspect, cationic lipids for use in the LNPs of the present disclosure are compounds of Formula (III):

[0138] wherein:

[0139] nl is an integer of 2 to 6,

[0140] n2 is an integer of 0 to 2,

[0141] n3 is an integer of 0 to 2,

[0142] L is — C(O)O— or — NHC(0)0—

[0143] Ra is a linear C5-13 alkyl group, a linear C 13-17 alkenyl group or a linearC17 alkadienyl group,

[0144] Rb is a linear C2-9 alkyl group,

[0145] Rc is a hydrogen atom or a linear C2-9 alkyl group,

[0146] Rd is a hydrogen atom or a linear C2-9 alkyl group,

[0147] Re is a linear C2-9 alkyl group, and

[0148] Rf is a linear C2-9 alkyl group, or a salt thereof.

[0149] In another aspect, cationic lipids for use in the LNPs of the present disclosure include:

[0150] and salts thereof.

[0151] In another aspect, cationic lipids for use in the LNPs of the present disclosure include:(compound 31)

[0152] and salts thereof.

[0153] In another aspect, cationic lipids for use in the LNPs of the present disclosure are described in WO 2011 / 153493.

[0154] In another aspect, cationic lipids for use in the LNPs of the present disclosure include:n = 0-2n = 0-2n = 0-2

[0155] In another aspect, cationic lipids for use in the LNPs of the present disclosure are described in Table 3.Table 3. Cationic Lipids

[0156] and salts thereof.

[0157] In another aspect, cationic lipids for use in the LNPs of the present disclosure include:

[0158] and salts thereof.

[0159] In another aspect, cationic lipids for use in the LNPs of the present disclosure are described in WO 2013 / 126803.

[0160] In another aspect, cationic lipids for use in the LNPs of the present disclosure include:

[0161] and salts thereof.

[0162] In another aspect, cationic lipids for use in the LNPs of the present disclosure is:

[0163] and a salt thereof.

[0164] In another aspect, cationic lipids for use in the LNPs of the present disclosure include K-E12, H-A12, Y-E12, G-O12, K-A12, R-A12, cKK-E12, cPK-E12, PK1K-E12, PK500-E12, cQK-E12, cKK-A12, KK-A12, PK-4K-E12, cWK-E12, PK500-O12, PK1K- O12, cYK-E12, cDK-E12, cSK-E12, cEK-E12, cMK-E12, cKK-012, cIK-E12, cKK-E10, cKK-E14, and cKK-E16 as described in Dong et al., Proc Natl Acad Sci USA.2014 Apr. 15; 111(15):5753.

[0165] In another aspect, cationic lipids for use in the LNPs of the present disclosure include C14-98, C18-96, C14-113, C14-120, C14-120, C14-110, C16-96, and C12-200 as described in Love K T et al. (Proc Natl Acad Sci USA.2010 May 25; 107(21):9915).

[0166] In another aspect, cationic lipids for use in the LNPs of the present disclosure compounds of Formula (I):

[0167] wherein:

[0168] L1is a C1-22 alkylene group, a C2-22 alkenylene group or a C3-22 alkadienylene group,

[0169] n is an integer of 0 or 1,

[0170] R1is

[0171] (1) a hydrogen atom,

[0172] (2) a linear C1-22alkyl group optionally substituted by one or two substituents selected from a linear C1-22 alkyl group and a linear C2-22 alkenyl group,

[0173] (3) a linear C2-22 alkenyl group optionally substituted by one or two substituents selected from a linear C1-22alkyl group and a linear C2-22alkenyl group, or

[0174] (4) a linear C3-22 alkadienyl group optionally substituted by one or two substituents selected from a linear C1-22 alkyl group and a linear C2-22 alkenyl group,

[0175] R2is —CH2—O—CO—R5, —CH2—CO—O—R5or —R5,

[0176] R3is a hydrogen atom, —CH2—O—CO—R6, —CH2—CO—O—R6or —R6,

[0177] R4is a hydrogen atom, —CH2—O—CO—R7, —CH2—CO—O—R7or —R7,

[0178] R5, R6and R7are each independently

[0179] (1) a linear C1-22alkyl group optionally substituted by one or two substituents selected from a linear C1-22 alkyl group and a linear C2-22 alkenyl group,

[0180] (2) a linear C2-22 alkenyl group optionally substituted by one or two substituents selected from a linear C1-22alkyl group and a linear C2-22alkenyl group,

[0181] (3) a linear C3-22 alkadienyl group optionally substituted by one or two substituents selected from a linear C1-22 alkyl group and a linear C2-22 alkenyl group, and R8 and R9 are each independently a C1-6alkyl group, or

[0182] (4) –R10–CO–O–R11or –R10–O–CO–R11,

[0183] R10represents an optionally substituted C1-16 alkylene group, an optionally substituted C4-16alkenylene group or an optionally substituted C7-16alkadienylene group, and

[0184] R11represents H, an optionally substituted C1-18 alkyl group, an optionally substituted C3-18 alkenyl group or an optionally substituted C15-18 alkadienyl group,

[0185] R8and R9are each independently a C1-6alkyl group, or a salt thereof.

[0186] L1is a C1-22 alkylene group, a C2-22 alkenylene group or a C3-22 alkadienylene group,

[0187] L1is preferably a C1-22alkylene group,

[0188] L1is more preferably a C1-12alkylene group,

[0189] L1is further preferably a C1-6 alkylene group,

[0190] n is an integer of 0 or 1,

[0191] n is preferably an integer of 1,

[0192] R1is

[0193] (1) a hydrogen atom,

[0194] (2) a linear C1-22alkyl group optionally substituted by one or two substituents selected from a linear C1-22 alkyl group and a linear C2-22 alkenyl group,

[0195] (3) a linear C2-22 alkenyl group optionally substituted by one or two substituents selected from a linear C1-22alkyl group and a linear C2-22alkenyl group, or

[0196] (4) a linear C3-22 alkadienyl group optionally substituted by one or two substituents selected from a linear C1-22 alkyl group and a linear C2-22 alkenyl group,

[0197] R1is preferably

[0198] (1) a hydrogen atom,

[0199] (2) a linear C1-22 alkyl group (preferably linear C6-12 alkyl group) optionally substituted by one or two linear C1-22alkyl groups (preferably linear C6-12alkyl groups), or

[0200] (3) a linear C2-22alkenyl group (preferably linear C6-12alkenyl group) optionally substituted by one or two linear C2-22 alkenyl groups (preferably linear C6-12 alkenyl groups),

[0201] R1is particularly preferably a hydrogen atom,

[0202] R2is —CH2—O—CO—R5, —CH2—CO—O—R5or —R5,

[0203] R2is preferably —CH2—O—CO—R5or —R5,

[0204] R2is more preferably —CH2—O—CO—R5,

[0205] R3is a hydrogen atom, —CH2—O—CO—R6, —CH2—CO—O—R6or —R6,

[0206] R3is preferably a hydrogen atom or —CH2—O—CO—R6or —R6,

[0207] R3is more preferably —CH2—O—CO—R6,

[0208] R4is a hydrogen atom, —CH2—O—CO—R7, —CH2—CO—O—R7or —R6,

[0209] R4is preferably a hydrogen atom or —CH2—O—CO—R7.

[0210] R4is more preferably —CH2—O—CO—R7,

[0211] R5, R6and R7are each independently

[0212] (1) a linear C1-22 alkyl group optionally substituted by one or two substituents selected from a linear C1-22 alkyl group and a linear C2-22 alkenyl group,

[0213] (2) a linear C2-22alkenyl group optionally substituted by one or two substituents selected from a linear C1-22alkyl group and a linear C2-22alkenyl group,

[0214] (3) a linear C3-22 alkadienyl group optionally substituted by one or two substituents selected from a linear C1-22alkyl group and a linear C2-22alkenyl group, or

[0215] (4) –R10–CO–O–R11or –R10–O–CO–R11.

[0216] R10represents an optionally substituted C1-16 alkylene group, an optionally substituted C4-16alkenylene group or an optionally substituted C7-16alkadienylene group, and

[0217] R11represents H, an optionally substituted C1-18 alkyl group, an optionally substituted C3-18 alkenyl group or an optionally substituted C15-18 alkadienyl group,

[0218] R5, R6and R7are each independently preferably

[0219] (1) a linear C1-22 alkyl group (preferably linear C4-18 alkyl group) optionally substituted by one or two linear C1-22 alkyl groups (preferably linear C1-10 alkyl groups),

[0220] (2) a linear C2-22alkenyl group (preferably linear C4-18alkenyl group),

[0221] (3) a linear C3-22alkadienyl group (preferably linear C4-18alkadienyl group), or

[0222] (4) –R10–CO–O–R11or –R10–O–CO–R11,

[0223] R10represents an optionally substituted C1-16alkylene group, an optionally substituted C4-16 alkenylene group or an optionally substituted C7-16 alkadienylene group, and

[0224] R11represents H, an optionally substituted C1-18alkyl group, an optionally substituted C3-18 alkenyl group or an optionally substituted C15-18 alkadienyl group,

[0225] R5, R6and R7are each independently more preferably

[0226] (1) a linear C1-22alkyl group (preferably linear C4-18alkyl group) optionally substituted by one or two linear C1-22alkyl groups (preferably linear C1-10alkyl groups),

[0227] (2) a linear C2-22 alkenyl group (preferably linear C4-18 alkenyl group), or

[0228] (3) –R10–CO–O–R11or –R10–O–CO–R11,

[0229] R10represents an optionally substituted C1-16alkylene group, an optionally substituted C4-16 alkenylene group or an optionally substituted C7-16 alkadienylene group, and

[0230] R11represents H, an optionally substituted C1-18alkyl group, an optionally substituted C3-18 alkenyl group or an optionally substituted C15-18 alkadienyl group.

[0231] R8 and R9 are each independently a C1-6 alkyl group,

[0232] R8and R9are each independently a C1-3alkyl group (preferably methyl).

[0233] Preferably, compound (I) is a compound of the above-mentioned formula (I) wherein

[0234] L1is a C1-22alkylene group (preferably C1-12alkylene group, more preferably Ce alkylene group),

[0235] n is an integer of 1,

[0236] R1is

[0237] (1) a hydrogen atom,

[0238] (2) a linear C1-22 alkyl group (preferably linear C6-12 alkyl group) optionally substituted by one or two linear C1-22 alkyl groups (preferably linear C6-12 alkyl groups), or

[0239] (3) a linear C2-22alkenyl group (preferably linear C6-12alkenyl group) optionally substituted by one or two linear C2-22 alkenyl groups (preferably linear C6-12 alkenyl groups),

[0240] R2is —CH2—O—CO—R5or —R5,

[0241] R3is a hydrogen atom or —CH2—O—CO—R6or —R6,

[0242] R4is a hydrogen atom or —CH2—O—CO—R7,

[0243] R5, R6and R7are each independently

[0244] (1) a linear C1-22alkyl group (preferably linear C4-18alkyl group) optionally substituted by one or two linear C1-22 alkyl groups (preferably linear C1-10 alkyl groups),

[0245] (2) a linear C2-22 alkenyl group (preferably linear C4-18 alkenyl group),

[0246] (3) a linear C3-22alkadienyl group (preferably linear C4-18alkadienyl group), or

[0247] (4) –R10–CO–O–R11or –R10–O–CO–R11,

[0248] R10represents an optionally substituted C1-16 alkylene group, an optionally substituted C4-16alkenylene group or an optionally substituted C7-16alkadienylene group, and

[0249] R11represents H, an optionally substituted C1-18 alkyl group, an optionally substituted C3-18alkenyl group or an optionally substituted C15-18alkadienyl group, and

[0250] R8and R9are each independently a C1-6alkyl group (preferably C1-3alkyl group, particularly preferably methyl).

[0251] In another aspect, compound (I) is a compound of the above-mentioned formula (I) wherein:

[0252] L1is a C1-12 alkylene group (preferably C1-6 alkylene group),

[0253] n is an integer of 1,

[0254] R1is a hydrogen atom,

[0255] R2is —CH2—O—CO—R5,

[0256] R3is —CH2—O—CO—R6,

[0257] R4is —CH2—O—CO—R7,

[0258] R5, R6and R7are each independently

[0259] (1) a linear C1-22 alkyl group (preferably linear C4-18 alkyl group) optionally substituted by one or two linear C1-22alkyl groups (preferably linear C1-10alkyl groups),

[0260] (2) a linear C2-22alkenyl group (preferably linear C4-18alkenyl group),

[0261] (3) a linear C3-22 alkadienyl group (preferably linear C4-18 alkadienyl group), or

[0262] (4) –R10–CO–O–R11or –R10–O–CO–R11,

[0263] R10represents an optionally substituted C1-16alkylene group, an optionally substituted C4-16 alkenylene group or an optionally substituted C7-16 alkadienylene group, and

[0264] R11represents H, an optionally substituted C1-18alkyl group, an optionally substituted C3-18alkenyl group or an optionally substituted C15-18alkadienyl group, and

[0265] R8 and R9 are each independently a C1-6 alkyl group (preferably C1-3 alkyl group, particularly preferably methyl).

[0266] In another aspect., compound (I) is a compound of the above-mentioned formula (I) wherein

[0267] L1is a C1-6 alkylene group,

[0268] n is an integer of 1,

[0269] R1is a hydrogen atom,

[0270] R2is —CH2—O—CO—R5,

[0271] R3is —CH2—O—CO—R6,

[0272] R4is —CH2—O—CO—R7,

[0273] R5, R6and R7are each independently

[0274] (1) a linear C1-22alkyl group (preferably linear C4-18alkyl group) optionally substituted by one or two linear C1-22alkyl groups (preferably linear C1-10alkyl groups),

[0275] (2) a linear C2-22 alkenyl group (preferably linear C4-18 alkenyl group), or

[0276] (3) –R10–CO–O–R11or –R10–O–CO–R11,

[0277] R10represents an optionally substituted C1-16alkylene group, an optionally substituted C4-16 alkenylene group or an optionally substituted C7-16 alkadienylene group, and

[0278] R11represents H, an optionally substituted C1-18alkyl group, an optionally substituted C3-18alkenyl group or an optionally substituted C15-18alkadienyl group, and

[0279] R8 and R9 are each independently a C1-3 alkyl group (preferably methyl).

[0280] In some aspects, a salt of the cationic lipids described above is a pharmacologically acceptable salt. Examples thereof include salts with inorganic bases (e.g., alkali metal salts such as sodium salt, potassium salt and the like; alkaline earth metal salts such as calcium salt, magnesium salt and the like; aluminum salt, ammonium salt), salts with organic bases (e.g., salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, tromethamine[tris(hydroxymethyl)methylamine], tert-butylamine, cyclohexylamine, benzylamine, dicyclohexylamine, N,N-dibenzyl ethylenediamine), salts with inorganic acids (e.g., salts with hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydrogen iodide acid, nitric acid, sulfuric acid, phosphoric acid), salts with organic acids (salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid), salts with basic amino acids (salts witharginine, lysine, ornithine) or salts with acidic amino acids (salts with aspartic acid, glutamic acid).

[0281] The ratio (mol %) of the cationic lipid to the total lipids present in the lipid nanoparticle of the present disclosure is, for example, about 10% to about 80%, about 20% to about 70%, or about 40% to about 60%; however, the ratio is not limited to these.

[0282] Only one kind of the above-mentioned cationic lipid may also be used or two or more kinds thereof may be used in combination. When multiple cationic lipids are used, the ratio of the whole cationic lipid is, for example, as mentioned above.

[0283] As used herein, the term "non-cationic lipid" refers a lipid other than a cationic lipid, and is a lipid that does not have a net positive electric charge at a selected pH such as physiological pH and the like. Examples of a non-cationic lipid used in the lipid nanoparticle of the present disclosure include, but are not limited to, a phospholipid, steroids, PEG lipid and the like.

[0284] To enhance the delivery of the nucleic acid payload into the target cell, tissue, organ, the phospholipid is not particularly limited as long as it stably maintains nucleic acid and does not inhibit fusion with cell membranes (plasma membrane and organelle membrane). For example, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol, phosphatidic acid, palmitoyloleoylphosphatidyl choline, lysophosphatidyl choline, lysophosphatidyl ethanolamine, dipalmitoylphosphatidyl choline, dioleoylphosphatidyl choline, distearoylphosphatidyl choline, dilinolenoylphosphatidyl choline and the like can be mentioned.

[0285] Phospholipids include, but are not limited to, distearoylphosphatidyl choline (DSPC), di oleoylphosphatidyl choline (DOPC), dipalmitoylphosphatidyl choline (DPPC), dioleoylphosphatidyl glycerol (DOPG), palmitoyloleoylphosphatidyl glycerol (POPG), dipalmitoylphosphatidyl glycerol (DPPG), dioleoyl-phosphatidyl ethanolamine (DOPE), palmitoyloleoylphosphatidyl choline (POPC), palmitoyloleoyl-phosphatidyl ethanolamine (POPE), and dioleoylphosphatidyl ethanolamine 4-(N-maleimide methyl)-cyclo hexane- 1 -carboxylate (DOPE-mal). In some aspects, the phospholipid is DOPC, DPPC, POPC, or DOPE.

[0286] The ratio (mol %) of the phospholipid to the total lipids present in the lipid nanoparticle of the present disclosure may be, for example, about 0% to about 90%, about 5% to about 30%, or about 8% to about 15%.

[0287] Only one kind of the above-mentioned phospholipid may be used or two or more kinds thereof may be used in combination. When multiple phospholipids are used, the ratio of the whole phospholipid is as mentioned above.

[0288] As the steroids, cholesterol, 5α-cholestanol, 5β-coprostanol, cholesteryl-(2′- hydroxy)-ethylether, cholesteryl-(4′-hydroxy)-butylether, 6-ketocholestanol, 5α- cholestane, cholestenone, 5α-cholestanone, 5β-cholestanone, and cholesteryl decanoate can be mentioned. In some aspects, the steroid is cholesterol.

[0289] The ratio (mol %) of the steroid to the total lipids present in the lipid nanoparticle of the present disclosure when steroids are present may be, for example, about 10% to about 60%, about 12% to about 58%, or about 20% to about 55%.

[0290] Only one kind of the above-mentioned steroid may be used or two or more kinds thereof may be used in combination. When multiple steroids are used, the ratio of the whole steroid is as mentioned above.

[0291] As used herein, the term "PEG lipid" means any complex of polyethylene glycol (PEG) and lipid. PEG lipid is not particularly limited as long as it has an effect of suppressing aggregation of the lipid nanoparticle of the present disclosure. For example, PEG conjugated with dialkyloxypropyl (PEG-DAA), PEG conjugated with diacylglycerol (PEG-DAG) (e.g., SUNBRIGHT GM-020 (NOF CORPORATION)), PEG conjugated with phospholipids such as phosphatidylethanolamine (PEG-PE), PEG conjugated with ceramide (PEG-Cer), PEG conjugated with cholesterol (PEG-cholesterol), or derivatives thereof, or mixtures thereof, mPEG2000-1,2-Di-O-alkyl-sn3-carbomoylglyceride (PEG- C-DOMG), 1-[8′-(1,2-dimyristoyl-3-propanoxy)-carboxamide-3′,6- dioxaoctanyl]carbamoyl-ω-methyl-poly(ethylene glycol) (2KPEG-DMG) and the like can be mentioned. PEG lipids include PEG-DGA, PEG-DAA, PEG-PE, PEG-Cer, and a mixture of these, e.g., a PEG-DAA conjugate selected from the group consisting of a PEG-didecyl oxypropyl conjugate, a PEG-dilauryl oxypropyl conjugate, a PEG- dimyristyl oxypropyl conjugate, a PEG-dipalmityl oxypropyl conjugate, a PEG-distearyl oxypropyl conjugate, and mixtures thereof.

[0292] The ratio (mol %) of the PEG lipid to the total lipids present in the lipid nanoparticle of the present disclosure may be, for example, about 0% to about 20%, about 0.1% to about 5%, or about 0.7% to about 2%.

[0293] The ratio (mol %) of the terminal reactive PEG lipid in the above-mentioned total PEG lipids is, for example, about 10% to about 100%, about 20% to about 100%, or about 30% to about 100%.

[0294] Only one kind of the above-mentioned PEG lipid may be used or two or more kinds thereof may be used in combination. When multiple PEG lipids are used, the ratio of the whole PEG lipid is as mentioned above.III. Cells of the Disclosure

[0295] Any cell type can be used in the compositions and methods disclosed herein. In some aspects, the cell is a liver cell. In some aspects, the cell is a hepatocyte.IV. Methods of the Disclosure

[0296] Some aspects of the present disclosure are directed to methods of producing vectors carrying DTS sequences of the present disclosure. Some aspects of the present disclosure are related to a method for treating liver disorders via introduction of vectors carrying DNA sequences of the present disclosure into liver cells. In some aspects, DNA sequences or vectors comprising the DNA sequences may be introduced to a subject in or with a pharmaceutically acceptable carrier. In some aspects, cells carrying DNA sequences or vectors comprising the DNA sequences may be introduced to a subject in or with a pharmaceutically acceptable carrier.

[0297] Some aspects of the present disclosure are directed to methods of treating a disease or condition in a subject in need thereof, comprising administering to the subject a composition disclosed herein. In some aspects, the method comprises administering a vector as disclosed herein.

[0298] In some aspects, the disease or condition is an inherited liver disorder, inherited systemic disorder, and acquired disorder.

[0299] In some aspects, the disease or condition is a cancer, e.g., the subject is afflicted with a cancer. In some aspects, the cancer is bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine,cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, or any combination thereof. In some aspects, the cancer is locally advanced. In some aspects, the cancer is metastatic. In some aspects, the cancer is refractory. In some aspects, the cancer is relapsed. In some aspects, the cancer is refractory or relapsed following one or more prior anti-cancer therapy. In some aspects, the one or more prior anti-cancer therapy comprises a standard of care therapy.

[0300] In some aspects, the compositions disclosed herein are administered in combination with an additional anti-cancer therapy. In some aspects, the additional anticancer therapy comprises a chemotherapy, an immunotherapy, a radiotherapy, a surgery, or any combination thereof. In some aspects, the additional anti-cancer therapy comprises a chemotherapy. In some aspects, the additional anti-cancer therapy comprises an immune-checkpoint inhibitor.

[0301] In some aspects, the subject is administered a chemotherapy prior to administering a DTS vector of the present disclosure carrying a gene of interest. In some aspects, the subject is administered an immuno-depleting chemotherapy prior to administering a DTS vector of the present disclosure carrying a gene of interest.

[0302] In some aspects, the method comprises administering to the subject a DTS sequence of the present disclosure carrying a gene of interest desired to be targeted to a nucleus of a liver cell, or nuclei of liver cells.

[0303] In some aspects, the sequence, vectors, or cells of the present disclosure are administered to a subject at a therapeutically effective dose.

[0304] The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Sambrooket al., ed. (1989) Molecular Cloning A Laboratory Manual (2nd ed.; Cold Spring Harbor Laboratory Press); Sambrook et al., ed. (1992) Molecular Cloning: A Laboratory Manual, (Cold Springs Harbor Laboratory, NY); D. N. Glover ed., (1985) DNA Cloning, Volumes I and II; Gait, ed. (1984) Oligonucleotide Synthesis; Mullis et al. U.S. Pat. No. 4,683,195; Hames and Higgins, eds. (1984) Nucleic Acid Hybridization; Hames and Higgins, eds. (1984) Transcription And Translation; Freshney (1987) Culture Of Animal Cells (Alan R. Liss, Inc.); Immobilized Cells And Enzymes (IRL Press) (1986); Perbal (1984) A Practical Guide To Molecular Cloning; the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Miller and Calos eds. (1987) Gene Transfer Vectors For Mammalian Cells, (Cold Spring Harbor Laboratory); Wu et al., eds., Methods In Enzymology, Vols. 154 and 155; Mayer and Walker, eds. (1987) Immunochemical Methods In Cell And Molecular Biology (Academic Press, London); Weir and Blackwell, eds., (1986) Handbook Of Experimental Immunology, Volumes I-FV; Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986));Crooke, Antisense drug Technology: Principles, Strategies and Applications, 2ndEd. CRC Press (2007) and in Ausubel et al. (1989) Current Protocols in Molecular Biology (John Wiley and Sons, Baltimore, Md.).

[0305] All of the references cited above, as well as all references cited herein, are incorporated herein by reference in their entireties.

[0306] The following examples are offered by way of illustration and not by way of limitation.EXAMPLESEXAMPLE 1Generation of DNA Nuclear Targeting Sequences

[0307] To generate potential DNA nuclear targeting sequences (DTSs) 881 hepatocyte- higher expressing genes were compared to higher expressing genes in other cell types using The Human Protein Atlas database (Online at the protein atlas.org, Funded by the Knut & Alice Wallenberg Foundation). After excluding the endoplasmic reticulum, golgi, cytosol, and secreted proteins, 76 candidate genes were identified having primary location in the nucleus. Those with no expression in immune cells, CNS, or reproductive organs led to identification of 15 transcription factors, nine nucleus and microtubule genes, and21 nuclear and vesicle genes. Finally, three genes were chosen to analyze for TFBS sequences. Additionally, a literature search was performed to compare previously identified sequences. Nine oligonucleotides, SEQ ID NOs: 1-9, listed in Table 2, were prepared as potential DTSs for incorporation into vectors.EXAMPLE 2Expression of ATP7B in Human Primary Hepatocytes

[0308] Vectors comprising an ATP7B gene were created carrying at least one copy of each of SEQ ID NOs: 10-17. More specifically, DNA plasmids harboring a codon optimized human ATP7B gene were created with expression driven by the 3xCRM8 enhancer, human Transthyretin (TTR) promoter, and minute virus of mice (MVM) intron, were cloned with inserts of the DTS sequences, SEQ ID NOs: 10-17. These constructs were cloned into the pUC57 plasmid for expression in mammalian cells as pictorially represented in FIG. 1. The WPREmut6 AATG gene, a post-transcriptional regulator gene that enhances expression of transgenes was cloned upstream of the bGH pA gene encoding bovine growth hormone specialized termination signal, also upstream of an identification sequence and either the 3NF positive control or the DTS sequences. The 3NF sequence is a short sequence that interacts with the trans factor nuclear factor KB (NFKB) and is known to enhance nuclear import. For the positive control, a copy of 3NF was inserted upstream of the 3xCRM8 enhancer and downstream of the ID tag sequence. A control lacking 3NF or the DTS sequences was created as a negative control. Cloning was achieved using standard molecular cloning techniques via restriction enzyme and / or PCR-based methods. Selected clones were confirmed by restriction enzyme and Sanger sequencing. Maxi preps of plasmid DNA were generated by external vendors (Aldevron or Genewiz) and resuspended in IxTE buffer. Plasmids were amplified by external vendors as endotoxin-free. Plasmids sizes ranged from 8,580 bp to 8,738 bp as indicated in Table 4. A plasmid harboring the DTS from SV40 was used as a positive control.

[0309] Plasmids were encapsulated in LNP formulations. To produce the LNPs, the ionizable-lipids included Lipid 1, the helper lipid was DOPC (Avanti Polar Lipids), and the structural lipid was cholesterol (Sigma Aldrich). These lipids and PEG-DMG were dissolved in ethanol to make 25 mM stock of each respectively which were mixed at a molar ratio of the ionizable / helper / structural / PEG-DMG of 50 / 10 / 38.5 / 1.5. DNA plasmids was diluted in 25 mM sodium acetate buffer (pH 5). The lipid mixture andnucleic acid solution were mixed using a microfluidic micromixer (Precision Nanosystems, Vancouver, BC, Canada) at room temperature with a flow rate ratio of 3 mL / min:9 mL / min to afford a dispersion containing lipid nanoparticles (LNPs) encapsulating respective nucleic acid. LNPs obtained were either dialyzed or filtered through Amicon U-15 filters (30 kDa or 100 kDa, cellulose) tube at 2000 x g 4°C for at least 30 minutes to remove excess ethanol and replace buffer with PBS. Sterile sucrose solution (20 % final volume) was added to the formulations as cryoprotectant. Subsequently, formulations were filtered through 0.2 pm syringe filter. Quant-iT™ PicoGreen dsDNA assay kit (Thermo Fisher Scientific) was used as manufacturer's protocol to quantify amount of nucleic acid encapsulated in the LNPs. The particle size and PDI of the LNPs were measured by using a Zetasizer Ultra Zs Xplorer (Malvern Instruments Limited). The formulations were kept at -80° C until used for in vitro experiments. Plasmid size, LNP size, polydensity index (PDI), and encapsulation efficiency (EE) is presented in Table 4. Nitrogen to oligonucleotide phosphate (N:P) ratios were 4.Table 4. LNP Attributes

[0310] Cryo Human Primary hepatocytes (Gibco, HU8360) were seeded into collagen- coated clear flat-bottom 96-well plates at a density of 60000 cells / well in primaryhepatocyte thawing and plating medium (Gibco, CM3000) and grown for 16 hours (h) at 37° C and 5% CO2. One pg of the LNP encapsulated DNA plasmids was mixed with 10% Human PB serum and added into each individual well (4 replicates per DNA construct). Medium was exchanged after 72 hours (h) to remove LNP encapsulated DNA plasmids and replaced with primary hepatocyte maintenance medium (Gibco, CM4000) and incubated for an additional 72 h. Cells were collected at 160 h after adding LNP encapsulated DNA plasmids. Cells were stored at -80° C until analysis. Cells were lysed using RIPA buffer (Thermo Fisher Scientific, #89901). ATP7B was quantified using MSD, a modified ELISA method wherein electrochemiluminescence (ECL) is used as a detection technique. Total soluble protein was quantified using BCA protein assay kit (Thermo Fisher Scientific, #A53225). Amount of ATP7B expressed in the nuclei of the cells is shown in FIG. 2 as picogram (pg) ATP7B per pg of cell protein. Codon optimized ATP7B gene sequences, example including SEQ ID NOs: 18, 20, 22, 24, 26, and 28, were cloned into vectors as described above and encapsulated in the LNP formulations. These codon optimized sequences increased protein expression in cells as compared to the wildtype ATP7B gene protein expression levels.EXAMPLE 3Expression of Luciferase and GLA in Human Primary Hepatocytes

[0311] DNA plasmids harboring the Luciferase:P2A:GLA transgene, wherein expression is driven by the ubiquitous promoter CAG, were cloned to carry the DTS sequences, SEQ ID NOs: 10-17, using standard molecular cloning techniques via restriction enzyme and / or PCR-based methods as pictorially represented in FIG. 3. Selected clones were confirmed by restriction enzyme and Sanger sequencing. Mega preps of plasmid DNA were generated using Qiagen Plasmid Mega Kit and resuspended in IxTE buffer. Plasmid were run for endotoxin using the Limulus Amoebocyte Lysate test (LAL) from Charles River (Wilmington, MA, USA). The highest endotoxin level was < 0.0167 EU / ug DNA.

[0312] DNA Nanoplasmids™ (Aldervron) harboring the Luciferase:P2A:GLA expression cassette plus the different DTS sequences, SEQ ID NOs: 10-17, were cloned into Nanoplasmid constructs and generated using Nature Technologies. Nanoplasmid constructs were confirmed by Sanger sequencing. Sizes of the DNA plasmid and nanoplasmids are presented in Tables 5 and 6.Table 5. Luciferase Expression Plasmid LNPs SpecificationsTable 6. Luciferase Expression Nanoplasmid LNPs Specifications

[0313] Plasmids were encapsulated in LNP formulations. To produce the LNPs, the ionizable-lipids included Lipid 1, the helper lipid was DOPC (Avanti Polar Lipids), and the structural lipid was cholesterol (Sigma Aldrich). These lipids and PEG-DMG weredissolved in ethanol to make 25 mM stock of each respectively which were mixed at a molar ratio of the ionizable / helper / structural / PEG-DMG 60 / 10.6 / 28 / 1.4. DNA plasmids and nanoplasmids were diluted in 20 mM sodium acetate buffer (pH 5). The lipid mixture and nucleic acid solution were mixed using a microfluidic micromixer (Precision Nanosystems, Vancouver, BC, Canada) at room temperature with a flow rate ratio of 3 ml / min:6 mL / min to afford a dispersion containing lipid nanoparticles (LNPs) encapsulating respective nucleic acid. LNPs obtained were dialyzed against PBS at 4° C overnight, filtered through 0.2 um syringe filter, then concentrated with Amicon Ultra-4 Centrifugal Filters (100 kDa) at 1000 g, RT, for at least 45 min. Sterile sucrose solution (20% final volume) was added to the formulations as cryoprotectant. The formulations were kept at -80° C until characterization or further experiments. Quant-iT™ PicoGreen dsDNA assay kit (Thermo Fisher Scientific) was used as manufacturer's protocol to quantify amount of nucleic acid encapsulated in the LNPs. The particle size and PDI of the LNPs were measured by using a Zetasizer Ultra (Malvern Instruments Limited). Plasmid (P) size, Nanoplasmid (NP) size, LNP size, PDI, DNA concentration, and % encapsulation is summarized in Tables 5 and 6.

[0314] Male Human Cryoplateable Hepatocytes (BioIVT, M00995) were thawed and pelleted by centrifugation (100 RPM, 10 minutes) in cryoplateable hepatocyte recovery media (CHRM) and re-suspended in William's E Media (phenol-free) with primary hepatocyte thawing and plating supplements (ThermoFisher, CM3000) to 875,000 cells / mL. Cells were plated on collagen-coated flat-bottom 24-well plates (215,000 cells / well) and allowed to adhere between 6 and 18 h. To generate the Matrigel sandwich overlay, wells were gently washed, and hepatocytes were incubated with William's E Media with primary hepatocyte maintenance supplements (ThermoFisher, CM4000) and Matrigel (Corning, Phenol-Free) at 0.35 mg / mL for 2-4 h. Media was then exchanged with hepatocyte maintenance media. Prior to treatment, 0.25 pg of LNP-formulated plasmid DNA was mixed with 30 ug / mL ApoE for 3 hours at room temperature to facilitate protein corona formation. Between 0.5 and 10 ug / mL of ApoE-LNP were then added to each well for transfection for 6 h before wells were then washed with PBS and maintenance media re-added to each well. Wells were then incubated for 96 h without media changes and media was collected for an alpha-galactosidase assay. Cells were then trypsinized, pelleted, and gently lysed in 0.1% Triton X-100 to separate the nuclei from the cytoplasm. Nuclei were collected via centrifugation (10,000 RPM, 30 seconds) andfrozen for DNA isolation. A luciferase assay was performed on the cytoplasmic portion of the cell lysate. Each plasmid construct experiment was replicated twice. As an indicator of GLA expression, luciferase activity in the cytoplasm was measured in duplicate via luminescence in relative light units (RLU) following plasmid transformation into cells as shown in FIG. 4. Luciferase activity in the cytoplasm was measured in triplicate via luminescence in relative light units following Nanoplasmid transformation into cells as shown in FIGs. 5 A-5B with luciferase luminescence represented as RLU in FIG. 5 A, and luciferase represented as RFU / pg protein in FIG. 5B.

[0315] FIG. 6 summarizes results obtained from plasmid expression assays conducted in Examples 2 and 3. Luciferase luminescence was measured as an indicator of GLA expression (gray bars, first in each set with left y axis data labels) and ATP7B protein measured as indicator of expression of ATP7B (right hand bars in each set with right y axis data labels). All DTS and TFBS sequences showed increased expression above the negative control (No DTS) in at least one of the assays and several showed increased expression above the positive control (3NF) indicating increased delivery compared to prior constructs.

[0316] It is to be appreciated that the Detailed Description section, and not the Summary and Abstract sections, is intended to be used to interpret the claims. The Summary and Abstract sections may set forth one or more but not all exemplary aspects of the present disclosure as contemplated by the inventor(s), and thus, are not intended to limit the present disclosure and the appended claims in any way.

[0317] The foregoing description of the specific aspects will so fully reveal the general nature of the disclosure that others can, by applying knowledge within the skill of the art, readily modify and / or adapt for various applications such specific aspects, without undue experimentation, without departing from the general concept of the present disclosure. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed aspects, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance.

[0318] The breadth and scope of the present disclosure should not be limited by any of the above-described exemplary aspects, but should be defined only in accordance with the following claims and their equivalents.

[0319] The contents of all cited references (including literature references, U.S. or foreign patents or patent applications, and websites) that are cited throughout this application are hereby expressly incorporated by reference as if written herein in their entireties for any purpose, as are the references cited therein. Where any inconsistencies arise, material literally disclosed herein controls.

[0320] While various specific aspects have been illustrated and described, the above specification is not restrictive. It will be appreciated that various changes can be made without departing from the spirit and scope of the invention(s). Many variations will become apparent to those skilled in the art upon review of this specification.

Claims

WHAT IS CLAIMED:

1. An expression vector comprising a DNA nuclear targeting sequence (DTS) region, wherein the DTS region comprises a transcription factor binding sequence (TFBS) consensus sequence of any one of SEQ ID NOs: 1-9.

2. The expression vector of claim 1, wherein the DTS region comprises one TFBS consensus sequence, two TFBS consensus sequences, three TFBS consensus sequences, four TFBS consensus sequences, five TFBS consensus sequences, six TFBS consensus sequences, seven TFBS consensus sequences, eight TFBS consensus sequences, nine TFBS consensus sequences, 10 TFBS consensus sequences, 11 TFBS consensus sequences, 12 TFBS consensus sequences, 13 TFBS consensus sequences, 14 TFBS consensus sequences, or 15 TFBS consensus sequences.

3. The expression vector of claim 1 or 2, wherein the DTS region comprises eight TFBS consensus sequences of SEQ ID NO: 1; seven TFBS consensus sequences of SEQ ID NO: 2; eight TFBS consensus sequences of SEQ ID NO: 3; seven TFBS consensus sequences of SEQ ID NO: 4; seven TFBS consensus sequences of SEQ ID NO: 5; eight TFBS consensus sequences of SEQ ID NO: 6; four TFBS consensus sequences of SEQ ID NO: 7 and four TFBS consensus sequences of SEQ ID NO: 8; or eight TFBS consensus sequences of SEQ ID NO: 9.

4. The expression vector of any one of claims 1-3, wherein one or more of the TFBS consensus sequences are separated from each other by a spacer having a sequence of one nucleotide, two nucleotides, three nucleotides, four nucleotides, five nucleotides, six nucleotides, seven nucleotides, eight nucleotides, nine nucleotides, or 10 nucleotides.

5. The expression vector of claim 4, wherein the spacer has a nucleotide sequence of AGA, TCG, GAC, CTA, ACT, TGC or GTA.

6. The expression vector of any one of claims 1-5, further comprising a promoter.

7. The expression vector of claim 6, wherein the promoter is suitable for gene expression in the liver.

8. The expression vector of any one of claims 1-7, further comprising a gene of interest.

9. The expression vector of claim 8, wherein the gene of interest is expressed in the liver.

10. The expression vector of claim 8 or 9, wherein the gene of interest is ATP7B or a codon optimized version thereof.

11. The expression vector of claim 10, wherein the ATP7B gene comprises the sequence of any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28.

12. The expression vector of claim 10, wherein the ATP7B gene encodes a polypeptide comprising the sequence of any one of SEQ ID NOs: 19, 21, 23, 25, 27 and 29, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 19, 21, 23, 25, 27 and 29.

13. The expression vector of claim 8 or 9, wherein the gene of interest is GLA.

14. The expression vector of any one of claims 1-13, further comprising a post-transcriptional regulatory element.

15. The expression vector of claim 14, wherein the post-transcriptional regulatory element is derived from WPRE.

16. The expression vector of any one of claims 1-14, further comprising a termination signal.

17. The expression vector of claim 16, wherein the termination signal is derived from bGH pA.

18. The expression vector of any one of claims 1-17, wherein the expression vector is a plasmid, nanoplasmid, or viral vector.

19. A lipid nanoparticle formulation comprising the expression vector of any one of claims 1-20. A cell comprising the expression vector of any one of claims 1-18.

21. A liver cell comprising the expression vector of any one of claims 1-18.

22. An expression vector comprising a DTS region, wherein the DTS region comprises the sequence of any one of SEQ ID NOs: 10-17, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 10-17.

23. The expression vector of claim 22, further comprising a promoter.

24. The expression vector of claim 23, wherein the promoter is suitable for gene expression in the liver.

25. The expression vector of any one of claims 22-24, further comprising a gene of interest.

26. The expression vector of claim 25, wherein the gene of interest is expressed in the liver.

27. The expression vector of claim 25 or 26, wherein the gene of interest is ATP7B or a codon optimized version thereof.

28. The expression vector of claim 27, wherein the ATP7B gene comprises the sequence of any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28.

29. The expression vector of claim 27, wherein the ATP7B gene encodes a polypeptide comprising the sequence of any one of SEQ ID NOs: 19, 21, 23, 25, 27 and 29, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 19, 21, 23, 25, 27 and 29.

30. The expression vector of claim 25 or 26, wherein the gene of interest is GLA.

31. The expression vector of any one of claims 22-30, further comprising a post- transcriptional regulatory element.

32. The expression vector of claim 31, wherein the post-transcriptional regulatory element is derived from WPRE.

33. The expression vector of any one of claims 22-32, further comprising a termination signal.

34. The expression vector of claim 33, wherein the termination signal is derived from bGH pA.

35. The expression vector of any one of claims 22-34, wherein the expression vector is a plasmid, nanoplasmid, or viral vector.

36. A lipid nanoparticle formulation comprising the expression vector of any one of claims 22-35.

37. A cell comprising the expression vector of any one of claims 22-35.

38. A liver cell comprising the expression vector of any one of claims 22-35.

39. A nucleic acid molecule comprising the sequence of any one of SEQ ID NOs: 1-9.

40. A nucleic acid molecule comprising the sequence of any one of SEQ ID NOs: 10-17, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 10-17.

41. A nucleic acid molecule comprising the sequence of any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28.

42. A method for expression of a gene of interest in a cell, comprising introducing an expression vector comprising a promoter, a gene of interest, and a DTS region to the cell, wherein the DTS region comprises a TFBS consensus sequence of any one of SEQ ID NOs: 1-9.

43. A method for expression of a gene of interest in a cell, comprising introducing an expression vector comprising a promoter, a gene of interest, and a DTS region to the cell, wherein the DTS region comprises the sequence of any one of SEQ ID NOs: 10-17, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 10-17.

44. A method for introducing a gene of interest into the nucleus of a cell, comprising introducing an expression vector comprising a promoter, a gene of interest, and a DTS region to the cell, wherein the DTS region comprises a TFBS consensus sequence of any one of SEQ ID NOs: 1-9.

45. A method for introducing a gene of interest into the nucleus of a cell, comprising introducing an expression vector comprising a promoter, a gene of interest, and a DTS region to the cell, wherein the DTS region comprises the sequence of any one of SEQ ID NOs: 10-17, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 10-17.

46. The method of any one of claims 42-45, wherein the gene of interest is ATP7B or a codon optimized version thereof.

47. The method of claim 46, wherein the ATP7B gene comprises the sequence of any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 18, 20, 22, 24, 26 and 28.

48. The method of claim 46, wherein the ATP7B gene encodes a polypeptide comprising the sequence of any one of SEQ ID NOs: 19, 21, 23, 25, 27 and 29, or a sequence having at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity to any one of SEQ ID NOs: 19, 21, 23, 25, 27 and 29.

49. The method of any one of claims 42-45, wherein the gene of interest is GLA.

50. The method of any one of claims 42-49, wherein the cell is a liver cell.

Citation Information

Patent Citations

  • Symmetric ionizable cationic lipid for RNA delivery

    US20150239834A1

  • Process for amplifying, detecting, and / or-cloning nucleic acid sequences

    US4683195A

  • Improved amino lipids and methods for the delivery of nucleic acids

    WO2010042877A1

  • Novel lipids and compositions for the delivery of therapeutics

    WO2010054401A1

  • Biodegradable lipids for the delivery of active agents

    WO2011153493A2